EU HTA regulation: international preparatory meeting in Cologne

17 June 2022 - At the invitation of IQWiG, 41 envoys from European HTA organisations and two from the EU ...

Read more →

Post-menopausal osteoporosis: advantages of teriparatide over risedronate sodium

2 June 2022 - Preliminary report on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab is available. Please submit ...

Read more →

Application accompanying data collection in the case of market access for several active substances in a class: IQWiG presents a concept

27 May 2022 - The institute recommends platform studies under a master's protocol. ...

Read more →

EUnetHTA relative effectiveness assessments: efforts to increase usability, transparency and inclusiveness

26 May 2022 - The objective of the European Network for Health Technology Assessment (EUnetHTA) Joint Action 3 (JA3) was to ...

Read more →

G-BA certifies active ingredients against breast and oesophageal cancer as having a high additional benefit

19 May 2022 - The Federal Joint Committee (G-BA) has rated the patient-relevant additional benefit of two active ingredients for cancer ...

Read more →

Methods paper: new version 6.1 becomes effective – English translation now available

2 May 2022 - The amendments concern, among other things, the approach to evidence searches for clinical practice guidelines. New ...

Read more →

European collaboration on health technology assessment: looking backward and forward

19 April 2022 - The establishment of health technology assessment has been an important topic in Europe for many years. ...

Read more →

Supply related data in manufacturer dossiers: things are not going smoothly yet

19 April 2022 - The criteria for supply related data established by IQWiG in 2020 were positively received in science.  ...

Read more →

Lenvatinib and pembrolizumab in endometrial cancer: patients live significantly longer

19 April 2022 - There is an indication of a considerable added benefit compared to doxorubicin or paclitaxel. Compared to ...

Read more →

Prospective measures to combat rising drug prices in Germany

13 April 2022 - This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to ...

Read more →

Bluebird Bio has serious cash flow concerns; inability to strike reimbursement deals in Europe partly to blame

3 April 2022 - Bluebird bio is a highly innovative biotechnology company which develops gene therapies for several rare genetic ...

Read more →

Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients

15 March 2022 - Hansa Biopharma completes the AMNOG reimbursement process for Idefirix in Germany. ...

Read more →

Criticism of study planning: patient-reported endpoints are often collected far too briefly

3 March 2022 - A striking example: abemaciclib in advanced breast cancer. Shortened data on quality of life, symptoms and side ...

Read more →

Triple negative breast cancer: survival benefit with sacituzumab govitecan

1 March 2022 - Those affected survive a median of twelve months compared to seven in the control group. Overall, ...

Read more →

COVID-19 vaccines: individual patient data should be submitted to the European Medicines Agency

24 February 2022 - An interesting letter to the Editor of the BMJ from the Head of Drug Assessment at ...

Read more →